In honor of Martin Luther King Jr. Day, Dr. Kathi A. Earles visited UF’s Bob Graham Center for Public Services Thursday ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult and pediatric patients aged ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

The FDA has approved GSK’s anti-IL-5 antibody depemokimab for the treatment of severe eosinophilic asthma in patients 12 and older. The drug will carry the brand name Exdensur. Exdensur is indicated ...

Thomas Ritz, PhD, University Distinguished Professor of psychology at Southern Methodist University in Dallas, was the featured speaker. His talk, titled “Asthma: Insights Into the Mind-Body ...

DENVER — A brief universal screening for asthma, even in a community with an already high prevalence of asthma, can further improve identification of children with undiagnosed asthma, according to a ...

A groundbreaking international study has shown that a 2-in-1 budesonide-formoterol inhaler is far more effective than the standard salbutamol inhaler in children with mild asthma, cutting attacks by ...

Inhalers that combine providing immediate relief with a longer-term preventative effect are already recommended as the standard treatment for mild asthma among people aged 12 and above in the UK, US ...